![Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01731-4/MediaObjects/41591_2022_1731_Fig1_HTML.png)
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine
![Increase in suicide following an initial decline during the COVID-19 pandemic in Japan | Nature Human Behaviour Increase in suicide following an initial decline during the COVID-19 pandemic in Japan | Nature Human Behaviour](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41562-020-01042-z/MediaObjects/41562_2020_1042_Fig1_HTML.png)
Increase in suicide following an initial decline during the COVID-19 pandemic in Japan | Nature Human Behaviour
Peer review analyze: A novel benchmark resource for computational analysis of peer reviews | PLOS ONE
![Thinking Outside the Self-Report: Using Evaluation Plans to Assess Evaluation Capacity Building - Lori A. Wingate, Kelly Robertson, Michael FitzGerald, Lana Rucks, Takara Tsuzaki, Carla Clasen, Jeremy Schwob, 2022 Thinking Outside the Self-Report: Using Evaluation Plans to Assess Evaluation Capacity Building - Lori A. Wingate, Kelly Robertson, Michael FitzGerald, Lana Rucks, Takara Tsuzaki, Carla Clasen, Jeremy Schwob, 2022](https://journals.sagepub.com/cms/10.1177/10982140211062884/asset/images/large/10.1177_10982140211062884-fig3.jpeg)